검색
Black Diamond Therapeutics Inc
BDTX관심 목록에 추가
1.885USD
-0.015-0.79%
시장 운영 시간 09/24, 13:03（ET）
108.01M시가총액
손실P/E TTM
Black Diamond Therapeutics Inc 정보 회사
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Black Diamond Therapeutics Inc 프로필
종목 코드 BDTX
회사 이름Black Diamond Therapeutics Inc
상장일Jan 30, 2020
CEOVelleca (Mark A)
직원 수24
유형Ordinary Share
회계 연도 종료Jan 30
주소245 First Street, 18Th Floor
도시CAMBRIDGE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02142
전화16174175868
웹사이트https://www.blackdiamondtherapeutics.com/
종목 코드 BDTX
상장일Jan 30, 2020
CEOVelleca (Mark A)
Black Diamond Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
51.84K
+13.12%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
자주 묻는 질문
Black Diamond Therapeutics Inc의 상위 5대 주주는 누구인가요?
Black Diamond Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Dr. Ali Behbahani, M.D.
Black Diamond Therapeutics Inc(BDTX)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Black Diamond Therapeutics Inc의 주식을 보유한 기관은 총 265곳이며, 이들이 보유한 주식의 총 가치는 약 45.02M로 전체 발행 주식의 78.72%를 차지합니다. 이는 2025Q4 대비 -14972289.00 증가한 수치입니다.